Drug Trial Radar · NCT07851623
Evaluation of Safety, Side Effects, and How the Drug, Inhaled CHF10136, Is Absorbed, Modified and Removed From the Body in Healthy Adults and Adults With Asthma
Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Oct 2, 2026
Primary completion
Dec 27, 2027
Study completion Dec 27, 2027
Sponsor
- Lead sponsor
- Chiesi Farmaceutici S.p.A.Industry
- Sponsor type
- Industry
- First posted
- Oct 1, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study evaluates the safety and tolerability of CHF10136 administered by inhalation in healthy adults and adults with asthma. The study includes single-dose, multiple-dose, and repeated-dose treatment periods and will also characterize the pharmacokinetic profile of CHF10136.
Conditions
- Asthma
- Healthy Volunteers
Interventions
CHF10136Drug
CHF10136 powder for inhalation administered orally using a Dry Powder Inhaler.
CHF10136 matched placeboDrug
Matching placebo powder for inhalation administered using a Dry Powder Inhaler.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-Emergent Adverse EventsTime frame: Part 1, 2 and 3: Day - 28 to Day - 2 (Screening Visit), Day -1, Day 1, Day 2, Day 3, Day 4, and Day 8 (Follow-up Visit)
- Change From Baseline in Systolic Blood Pressure and Diastolic Blood PressureTime frame: Part 1, 2 and 3:Day - 28 to Day - 2 (Screening Visit), Day -1, Day 1, Day 2, Day 3, Day 4, and Day 8 (Follow-up Visit)
- Change From Baseline in Electrocardiogram Parameters: HR (Heart Rate)Time frame: Part 1, 2 and 3:Day - 28 to Day - 2 (Screening Visit), Day -1, Day 1, Day 2, Day 3, Day 4, and Day 8 (Follow-up Visit)
- Change From Baseline in Electrocardiogram Parameters: Intervals recorded: PR, QT, QRS duration, QTcF (Fridericia corrected QT interval)Time frame: Part 1: Day 1 to Day 2 - Part 2 & 3: Day 1 to Day N + 1 (Day after the last treatment intake)
- Change From Baseline in Clinical Laboratory ParametersTime frame: Part 1: Screening visit, Day -1, Day 4 and Day 8 - Part 2 & 3: Screening Visit, Day -1, Day 4 , Day 7, Day N+1 (Day after the last treatment intake), Day N+7 (Follow-up Visit)
- Change From Baseline in Forced Expiratory Volume in One Second (FEV1)Time frame: Part 1: Screening Visit, Day 1 and Day 2 - Part 2& 3: Screening Visit, Day -1, Day 1 and Day N (the last day of treatment intake)
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Fortrea Leeds CRU
Leeds, United Kingdom · Recruiting
hVIVO
London, United Kingdom · Not yet recruiting
MEU
Manchester, United Kingdom · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.